-
公开(公告)号：US20150183878A1
公开(公告)日：2015-07-02
申请号：US14550703
申请日：2014-11-21
IPC分类号： C07K16/28
CPC分类号： C07K16/2863 , A61K31/337 , A61K39/39533 , A61K39/3955 , A61K39/39558 , A61K2039/505 , C07K16/28 , C07K2317/21 , C07K2317/24 , C07K2317/34 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/732 , C07K2317/734 , C07K2317/76 , C07K2317/92 , C12N5/12 , Y10S530/809 , A61K2300/00
摘要： Isolated antibodies that specifically binds to an extracellular conserved ligand binding region of a human Notch receptor and inhibits growth of a tumor are described. Also described are methods of treating cancer, the method comprising administering an anti-Notch antibody in an amount effective to inhibit tumor growth.
摘要翻译： 描述了特异性结合人Notch受体的细胞外保守配体结合区域并抑制肿瘤生长的分离的抗体。 还描述了治疗癌症的方法，该方法包括以有效抑制肿瘤生长的量施用抗Notch抗体。
-
公开(公告)号：US20130295105A1
公开(公告)日：2013-11-07
申请号：US13800454
申请日：2013-03-13
发明人： Austin L. GURNEY , Aaron Ken Sato , Fumiko Takada Axelrod , Timothy Charles Hoey , Sanjeev H. Satyal , Satyajit Sujit Kumar Mitra
IPC分类号： C07K16/30 , A61K45/06 , A61K39/395
CPC分类号： C07K16/28 , A61K31/00 , A61K31/337 , A61K31/7068 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K2039/505 , C07K16/2863 , C07K16/30 , C07K16/3015 , C07K16/3023 , C07K16/303 , C07K2299/00 , C07K2317/21 , C07K2317/24 , C07K2317/30 , C07K2317/34 , C07K2317/55 , C07K2317/565 , C07K2317/732 , C07K2317/734 , C07K2317/76 , C07K2317/92 , C07K2317/94 , C07K2319/30 , G01N33/5011 , A61K2300/00
摘要： Novel anti-cancer agents, including, but not limited to, antibodies, that bind to human frizzled receptors are provided. Novel epitopes within the human frizzled receptors which are suitable as targets for anti-cancer agents are also identified. Methods of using the agents or antibodies, such as methods of using the agents or antibodies to inhibit Wnt signaling and/or inhibit tumor growth are further provided.
-
公开(公告)号：US20130260455A1
公开(公告)日：2013-10-03
申请号：US13782671
申请日：2013-03-01
发明人： Austin L. GURNEY , Timothy Charles Hoey , Edward Thein Htun van der Horst , Aaron Ken Sato , Yuan Ching Liu , Maureen Fitch Bruhns , John A. Lewicki
IPC分类号： C07K16/28
CPC分类号： C07K16/22 , A61K31/337 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K2039/505 , A61N5/10 , C07H21/04 , C07K14/435 , C07K14/71 , C07K16/28 , C07K16/30 , C07K16/3046 , C07K16/462 , C07K16/464 , C07K2317/21 , C07K2317/24 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/734 , C07K2317/76 , C07K2317/92 , C12N5/0693 , C12N5/12 , C12N15/63 , C12N15/79 , C12N2501/998
摘要： The present invention relates to Notch-binding agents and Notch antagonists and methods of using the agents and/or antagonists for treating diseases such as cancer. The present invention provides antibodies that specifically bind to a non-ligand binding region of the extracellular domain of one or more human Notch receptor, such as Notch2 and/or Notch3, and inhibit tumor growth. The present invention further provides methods of treating cancer, the methods comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human Notch receptor protein and inhibits tumor growth.
-
公开(公告)号：US20210061903A1
公开(公告)日：2021-03-04
申请号：US16928452
申请日：2020-07-14
IPC分类号： C07K16/28 , A61K45/06 , A61K31/4745 , A61K31/7068 , A61K39/395 , C07K16/22 , A61K39/00 , A61K45/00 , C07K16/18 , C07K16/30
摘要： The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.
-
公开(公告)号：US09574009B2
公开(公告)日：2017-02-21
申请号：US15163301
申请日：2016-05-24
CPC分类号： C07K16/28 , A61K31/4745 , A61K31/7068 , A61K39/00 , A61K39/395 , A61K39/3955 , A61K45/00 , A61K45/06 , A61K2039/505 , C07K16/18 , C07K16/22 , C07K16/30 , C07K16/303 , C07K16/3046 , C07K2317/31 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92 , A61K2300/00
摘要： The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.
摘要翻译： 本发明涉及VEGF结合剂，DLL4结合剂，VEGF / DLL4双特异性结合剂，以及使用该药物治疗诸如癌症的疾病的方法。 本发明提供了特异性结合人VEGF的抗体，特异性结合人DLL4的抗体，以及特异性结合人VEGF和/或人类DLL4的双特异性抗体。 本发明还提供了使用这些药物来抑制肿瘤生长的方法。 还描述了治疗癌症的方法，其包括向具有肿瘤或癌症的患者施用治疗有效量的本发明的药剂或抗体。
-
公开(公告)号：US08975044B2
公开(公告)日：2015-03-10
申请号：US13800812
申请日：2013-03-13
发明人： Austin L. Gurney , Aaron Ken Sato , Fumiko Takada Axelrod , Timothy Charles Hoey , Sanjeev H. Satyal , Satyajit Sujit Kumar Mitra
IPC分类号： C12P19/34 , A61K38/00 , C07K16/30 , A61K31/00 , A61K39/395 , A61K45/06 , C07K16/28 , G01N33/50 , A61K39/00
CPC分类号： C07K16/28 , A61K31/00 , A61K31/337 , A61K31/7068 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K2039/505 , C07K16/2863 , C07K16/30 , C07K16/3015 , C07K16/3023 , C07K16/303 , C07K2299/00 , C07K2317/21 , C07K2317/24 , C07K2317/30 , C07K2317/34 , C07K2317/55 , C07K2317/565 , C07K2317/732 , C07K2317/734 , C07K2317/76 , C07K2317/92 , C07K2317/94 , C07K2319/30 , G01N33/5011 , A61K2300/00
摘要： Novel anti-cancer agents, including, but not limited to, antibodies, that bind to human frizzled receptors are provided. Novel epitopes within the human frizzled receptors which are suitable as targets for anti-cancer agents are also identified. Methods of using the agents or antibodies, such as methods of using the agents or antibodies to inhibit Wnt signaling and/or inhibit tumor growth are further provided.
摘要翻译： 提供了与人类卷曲受体结合的新型抗癌剂，包括但不限于抗体。 还鉴定了适合作为抗癌剂靶标的人类卷曲受体中的新表位。 进一步提供使用试剂或抗体的方法，例如使用该试剂或抗体抑制Wnt信号传导和/或抑制肿瘤生长的方法。
-
公开(公告)号：US08858941B2
公开(公告)日：2014-10-14
申请号：US13625417
申请日：2012-09-24
IPC分类号： A61K39/395 , C12P21/08 , C07K16/00 , C07K16/22 , C07K16/28 , C07K16/18 , A61K45/00 , A61K39/00
CPC分类号： C07K16/28 , A61K31/4745 , A61K31/7068 , A61K39/00 , A61K39/395 , A61K39/3955 , A61K45/00 , A61K45/06 , A61K2039/505 , C07K16/18 , C07K16/22 , C07K16/30 , C07K16/303 , C07K16/3046 , C07K2317/31 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92 , A61K2300/00
摘要： The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.
摘要翻译： 本发明涉及VEGF结合剂，DLL4结合剂，VEGF / DLL4双特异性结合剂，以及使用该药物治疗诸如癌症的疾病的方法。 本发明提供了特异性结合人VEGF的抗体，特异性结合人DLL4的抗体，以及特异性结合人VEGF和/或人类DLL4的双特异性抗体。 本发明还提供了使用这些药物来抑制肿瘤生长的方法。 还描述了治疗癌症的方法，其包括向具有肿瘤或癌症的患者施用治疗有效量的本发明的药剂或抗体。
-
公开(公告)号：US20130296536A1
公开(公告)日：2013-11-07
申请号：US13826432
申请日：2013-03-14
发明人： Austin L. GURNEY , Timothy Charles Hoey , Edward Thein Htun van der Horst , Aaron Ken Sato , Yuan Ching Liu , Maureen Fitch Bruhns , John A. Lewicki
IPC分类号： C07K16/22
CPC分类号： C07K16/22 , A61K31/337 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K2039/505 , A61N5/10 , C07H21/04 , C07K14/435 , C07K14/71 , C07K16/28 , C07K16/30 , C07K16/3046 , C07K16/462 , C07K16/464 , C07K2317/21 , C07K2317/24 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/734 , C07K2317/76 , C07K2317/92 , C12N5/0693 , C12N5/12 , C12N15/63 , C12N15/79 , C12N2501/998
摘要： The present invention relates to Notch-binding agents and Notch antagonists and methods of using the agents and/or antagonists for treating diseases such as cancer. The present invention provides antibodies that specifically bind to a non-ligand binding region of the extracellular domain of one or more human Notch receptor, such as Notch2 and/or Notch3, and inhibit tumor growth. The present invention further provides methods of treating cancer, the methods comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human Notch receptor protein and inhibits tumor growth.
-
公开(公告)号：US10730940B2
公开(公告)日：2020-08-04
申请号：US15847335
申请日：2017-12-19
IPC分类号： A61K39/395 , C07K16/22 , C07K16/28 , C07K16/46 , A61K45/06 , A61K31/4745 , A61K31/7068 , A61K39/00 , A61K45/00 , C07K16/18 , C07K16/30
摘要： The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.
-
公开(公告)号：US09879084B2
公开(公告)日：2018-01-30
申请号：US15401543
申请日：2017-01-09
CPC分类号： C07K16/28 , A61K31/4745 , A61K31/7068 , A61K39/00 , A61K39/395 , A61K39/3955 , A61K45/00 , A61K45/06 , A61K2039/505 , C07K16/18 , C07K16/22 , C07K16/30 , C07K16/303 , C07K16/3046 , C07K2317/31 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92 , A61K2300/00
摘要： The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.
-
-
-
-
-
-
-
-
-
搜索结果
26 条记录 (耗时 0.043 秒)
